Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
The US military has undertaken a campaign against alleged drug trafficking boats in the Pacific Ocean and Caribbean Sea using a variety of drones, gunships, and fighter jets, according to people ...
Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.
There was an error while loading. Please reload this page. Gemma is a family of lightweight, state-of-the-art open models from Google, built from the same research ...
The Hechinger Report covers one topic: education. Sign up for our newsletters to have stories delivered to your inbox. Consider becoming a member to support our nonprofit journalism. Writing can be ...
The Python Software Foundation warned users this week that threat actors are trying to steal their credentials in phishing attacks using a fake Python Package Index (PyPI) website. PyPI is a ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, marking a +2.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.54% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback